• DOI:10.1586/17474124.2014.925799
Corpus ID: 31633898

Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer

@article{Borazanci2014NabpaclitaxelAG,
  title={Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer},
  author={E. Borazanci and D. V. Von Hoff},
  journal={Expert Review of Gastroenterology & Hepatology},
  year={2014},
  volume={8},
  pages={739 - 747}
}

• E. Borazanci, D. V. Von Hoff
• Published 2014
• Medicine
• Expert Review of Gastroenterology & Hepatology

Adenocarcinoma of the pancreas or pancreatic cancer as we will refer to it here, is a cancer of poor prognosis with a high mortality, particularly in the advanced or metastatic setting. Until 2011 and the Phase III results of FOLFIRINOX, standard treatment options were limited to gemcitabine. Combination therapy had shown either a lack of or very limited improvement versus monotherapy with gemcitabine. With the positive results of the MPACT study in 2013 showing improved survival with nab… Expand

View on Taylor & Francis

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed